Norepinephrine Induces Lung Microvascular Endothelial Cell Death by NADPH Oxidase-Dependent Activation of Caspase-3

Andreia Z. Chignalia,1,2,3 Guy Weinberg,1 and Randal O. Dull1,2,3

1College of Medicine, Department of Anesthesiology, University of Illinois at Chicago, Chicago, Illinois, USA
2College of Medicine, Department of Anesthesiology, University of Arizona, Tucson, Arizona, USA
3College of Medicine, Department of Physiology, University of Arizona, Tucson, Arizona, USA

Correspondence should be addressed to Andreia Z. Chignalia; azchignalia@email.arizona.edu

Received 16 July 2019; Revised 15 November 2019; Accepted 3 January 2020; Published 12 February 2020

Copyright © 2020 Andreia Z. Chignalia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Norepinephrine (NE) is the naturally occurring adrenergic agonist that is released in response to hypotension, and it is routinely administered in clinical settings to treat moderate to severe hypotension that may occur during general anesthesia and shock states. Although NE has incontestable beneficial effects on blood pressure maintenance during hypotensive conditions, deleterious effects of NE on endothelial cell function may occur. In particular, the role of reactive oxygen species (ROS) and NADPH oxidase (Nox) on the deleterious effects of NE on endothelial cell function have not been fully elucidated. Therefore, we investigated the effects of NE on ROS production in rat lung microvascular endothelial cells (RLMEC) and its contribution to cell death. RLMEC were treated with NE (5 ng/mL) for 24 hours and ROS production was assessed by CellROX and DCFDA fluorescence. Nox activity was assessed by NADPH-stimulated ROS production in isolated membranes and phosphorylation of p47phox; cell death was assessed by flow cytometry and DNA fragmentation. Caspase activation was assessed by fluorescent microscopy. Nox1, Nox2, and Nox4 mRNA expression was assessed by real-time PCR. NE increased ROS production, Nox activity, p47phox phosphorylation, Nox2 and Nox4 mRNA content, caspase-3 activation, and RLMEC death. Phentolamine, an α1-adrenoreceptor antagonist, inhibited NE-induced ROS production and Nox activity and partly inhibited cell death while β-blockade had no effect. Apocynin and PEGSOD inhibited NE-induced caspase-3 activation and cell death while direct inhibition of caspase-3 abrogated NE-induced cell death. PEG-CAT inhibited NE-induced cell death but not caspase-3 activation. Collectively, these results indicate that NE induces RLMEC death via activation of Nox by α-adrenergic signaling and caspase-3-dependent pathways. NE has deleterious effects on RLMECs that may be important to its long-term therapeutic use.

1. Introduction

Norepinephrine (NE) is the endogenous catecholamine released by sympathetic nerve fibers in the vascular wall in response to acute reductions in blood pressure. Exogenous NE is commonly used to support blood pressure during shock due to its dual action on both α1- and β1-adrenoreceptors that, respectively, cause vasoconstriction and increase myocardial contractility, ultimately resulting in increased peripheral vascular resistance and cardiac output. However, studies in rats indicate that typical pressor doses of NE or epinephrine can alter pulmonary capillary integrity leading to accumulation of lung water and ultimately pulmonary edema [1, 2]. These reports reveal an important and yet unexplored area: the potential long-term side effects of the use of catecholamines in clinical settings. Whether NE exerts deleterious effects on vascular cells is still unknown and is worth of exploration as it may have direct bearing on the clinical use of catecholamines. In particular, understanding the potential deleterious effects of pathophysiologival concentrations of NE in lung endothelial cells may be critical as it has been shown that these cells develop dysfunction, and, specifically barrier failure, when acutely exposed to NE. Moreover, the lung endothelium uptakes approximately 30% of the circulating NE, making this organ an important target for NE.
The effects of NE on endothelial function have been related to increased reactive oxygen species (ROS) production. We have recently shown that, in rats, continuous infusion of NE for two hours leads to nitric oxide synthase (NOS) uncoupling in the lungs. Uncoupled NOS then drives superoxide anion generation leading to oxidative stress, endothelial dysfunction, and endothelial barrier disruption that ultimately causes pulmonary edema [2]. Additionally, it has been shown that NE increases ROS production by a NADPH oxidase1 (Nox1) dependent pathway in human peripheral mononuclear cells [3] and in rat endothelial cardiac cells [4]. Interestingly, ROS production by NE can be mediated either by α- [3] or β-adrenoceptors depending on the cell type [5].

The suprapharmacological concentrations of NE used in many studies have limited clinical significance. We therefore investigated the effects of a clinically relevant concentration of NE [6–8] on Nox activity and ROS production in endothelial cells and its contribution to endothelial cell death. Herein, we report that NE, in a concentration in the same order of magnitude as the ones found in human plasma of critically ill patients, can be toxic to rat lung microvascular endothelial cells.

2. Methods

2.1. Drugs and Reagents. Chemicals were the highest grade available. Norepinephrine bitartrate salt, apocynin, propranolol, phentolamine, superoxide dismutase-polyethylene glycol (PEG-SOD), and catalase-polyethylene glycol (PEG-CAT) were purchased from Sigma Chemicals. Phospho-p47phox (Ser370) was purchased from Invitrogen. Caspase-3 inhibitor III, was purchased from Santa Cruz Biotechnologies (Dallas, TX). FITC Annexin V/Dead Cell Apoptosis Kit®, CellROX® Green, and CellROX® Orange oxidation in a 96-well plate assay according to the manufacturer’s instructions. Phospho-p47phox (Ser370) was purchased from Invitrogen. Caspase-3 inhibitor III, was purchased from Santa Cruz Biotechnologies (Dallas, TX). FITC Annexin V/Dead Cell Apoptosis Kit®, CellROX® Green, and CellROX® Orange oxidation in a 96-well plate assay according to the manufacturer’s instructions. Phospho-p47phox (Ser370) was purchased from Invitrogen. Caspase-3 inhibitor III, was purchased from Santa Cruz Biotechnologies (Dallas, TX). FITC Annexin V/Dead Cell Apoptosis Kit®, CellROX® Green, and CellROX® Orange oxidation in a 96-well plate assay according to the manufacturer’s instructions. Phospho-p47phox (Ser370) was purchased from Invitrogen. Caspase-3 inhibitor III, was purchased from Santa Cruz Biotechnologies (Dallas, TX). FITC Annexin V/Dead Cell Apoptosis Kit®, CellROX® Green, and CellROX® Orange oxidation in a 96-well plate assay according to the manufacturer’s instructions.

2.2. Cell Culture. Rat lung microvascular endothelial cells (RLMEC) were purchased from VEC Technologies (Rensselaer, NY) and cultured with EB2 medium (Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum; cells were maintained in an incubator at 37°C, 5% CO2. Cells from passage 4 to 10 were used in these experiments. Experiments were performed using NE 5 ng/mL (15.7 nM). The concentration of NE was chosen based on a cell viability concentration-response curve, assessed by trypan blue, as the first dose capable of decreasing lung endothelial cell viability in vitro after 24 h of NE exposure (data not shown). This concentration is in the ng/mL order of magnitude, which is found in critically ill patients [6–8].

2.3. Measurement of Reactive Oxygen Species

2.3.1. CellROX®. ROS production was assessed by fluorescence via measurement of CellROX® oxidation in a 96-well plate assay according to the manufacturer’s instructions. RLMCE (10³ cells/well) were serum deprived for 24 hours and stimulated with NE 5 ng/mL for 5 to 120 minutes. To assess if NE induces superoxide anion or hydrogen peroxide generation, RLMEC were preincubated with PEG-SOD (25 U/mL) or PEG-CAT (200 U/mL) for 30 minutes before RLMEC exposure to NE for 5 minutes. Concentrations of PEG-SOD and PEG-CAT were chosen based on the literature [9]. To assess the contribution of α- and β-adrenoceptors, RLMEC were incubated with phentolamine (10⁻⁸ mol/L) or propranolol (10⁻⁸ mol/L) for 30 minutes before exposure to NE for 5 minutes. The concentration on phentolamine and propranolol was chosen based on a concentration-response curve as the lowest dose capable of inhibiting NE-inducing ROS production in RLMEC.

2.3.2. DCFDA. ROS production was assessed by the detection of carboxy-2’,7’, dichlorofluorescein fluorescence (DCF) by epifluorescence microscopy. RLMEC were plated in glass coverslips pretreated with 0.4% gelatin. Cells were serum deprived for 24 hours and stimulated with NE 5 ng/mL for 15 minutes. To assess if NE induces superoxide anion or hydrogen peroxide generation, RLMEC were preincubated with PEG-SOD (25 U/mL) or PEG-CAT (200 U/mL) for 30 minutes before RLMEC exposure to NE for 15 minutes. Concentrations of PEG-SOD and PEG-CAT were chosen based on the literature [9]. After stimulation with NE, cells were washed with HBSS buffer and incubated with 25 μM of carboxy-5-(and-6)-carboxy-2’,7’-dichlorodihydrofluorescein (carboxy-DCFDA) for 30 minutes. Cells were fixed in 10% methanol for 5 minutes and mounted in prolong anti-fade mounting media. Images were acquired by Leica microscope (DMI6000) using LAS X® software. Images were quantified with ImageJ (NIH) software. Data is presented as relative fluorescent units (RFU, fluorescence on 488 channel normalized by the number of cells in the field (assessed by DAPI staining)).

2.3.3. Nox Activity. Nox activity was assessed in membrane fractions as previously described [10, 11]. RLMEC were incubated with NE (5 ng/mL) for 5 up to 120 minutes. In specific studies, RLMEC were preincubated with phentolamine (10⁻⁸ mol/L) or propranolol (10⁻⁸ mol/L) before exposure to NE (5 ng/mL) for 5 minutes. Membrane fractions were isolated from RLMEC using Mem-PER™ Plus® Membrane Protein Extraction Kit according to the manufacturers’ instructions. Nox activity in membrane fractions was assessed by the kinetics of DHE oxidation in a 96-well plate fluorimeter. One hundred microliters of the membrane extract was added to each well, along with 0.12 μL DHE (10 mM), 25 μg/mL DNA, and 101.88 μL phosphate buffer (50 mM, pH 7.4). Fluorescence was read for 30 min (λex = 485 nm, λem = 595 nm). Three microliters of NADPH (2 mM/L) was then added and a new reading was performed for 30 min. The delta for the area under the curve (ΔAUC) was calculated (ΔAUC = AUC after NADPH –AUC before NADPH). ΔAUC was normalized by protein content in the sample. The results are expressed as percent-age of control.
2.4. Immunohistochemistry. RLMEC were plated in glass coverslips pretreated with 0.4% gelatin. When cells reached confluence, they were serum deprived for 24 h and incubated with PBS or NE (5 ng/mL) for 15 minutes. Cells were fixed with 4% paraformaldehyde and permeabilized with triton 0.1% in HBSS. Blocking of nonspecific binding sites was done with 5% normal goat serum. Cells were incubated with phospo-p47phox (Ser370) antibody overnight at 4°C. Cells were washed and incubated with Alexa Fluor™ 647 goat anti-rabbit antibody for 2 hours at room temperature followed up by incubation with DAPI. Slides were mounted and imaged on a Leica microscope (DMI6000) using LAS X® software. Images were quantified with ImageJ (NIH). Data is presented as relative fluorescent units (RFU, fluorescence on 647 channel normalized by the number of cells in the field (assessed by DAPI staining)).

2.5. Real-Time PCR. RNA was extracted by TRIZOL® (Invitrogen) and quantified using NanoDrop (Thermo Fisher Scientific). One-step real-time PCR was performed using Power SYBR™ Green RNA to C,™ RT-PCR kit (Applied Biosystems by Thermo Fisher Scientific) and the QuantiStudio 3 (Thermo Fisher Scientific). Primers were obtained from Integrated DNA Technologies (Corvalle, IA). Data were analyzed using the comparative cycle threshold (CT) method. Relative quantification to the control sample calibrator was calculated using the formula $2^{\Delta\Delta CT}$. Gene expression was normalized to the level of beta actin, which was used as an internal control. Data are presented as relative expression levels compared with the control.

2.6. Cell Viability and Cell Death. Cell viability was assessed by trypan blue staining. Results are expressed as percentage of viable cells. Cell death was assessed by annexin V and propidium iodide (PI) staining via flow cytometry using a commercially available kit (FITC Annexin V/Dead Cell Apoptosis Kit®) from Thermo Fisher Scientific. Apoptotic cells were detected by FragEL™ DNA Fragmentation Detection Kit Fluorescence TdT enzyme according to the manufacturer’s instructions and DNA fragmentation was assessed by electrophoresis. For these studies, RLMEC were incubated with NE 5 ng/mL or PBS for 24 hours. When required, cells were preincubated with PEG-SOD (25 U/mL) or PEG-CAT (200 U/mL) for 30 minutes before RLMEC exposure to NE.

2.7. Caspase Activation. Caspase-3 and caspase-7 activation were assessed by fluorescence microscopy using CellEvent™ kit (Invitrogen). RLMEC were exposed to NE 5 ng/mL for 24 hours in the presence or absence of phenotolamine (10⁻⁸ mol/L), apocynin (30 μmol/L), PEG-SOD (25 U/mL), or PEG-CAT (200 U/mL). Images were acquired by an upright fluorescence microscope (Olympus BX51) using Olympus Screen Saver software (Olympus).

2.8. Statistical Analysis. Data are presented as mean ± SD. Groups were compared using 1-way ANOVA or Student t test, as appropriate. Newman-Keuls post hoc test was used to compensate for multiple testing procedures. $p < 0.05$ was considered statistically significant.

3. Results

3.1. ROS Production. ROS production was measured in a real-time manner using CellROX® probe (Thermo Fisher Scientific) in RLMEC stimulated or not with NE. A two-fold increase in ROS production was observed as early as 5 minutes after exposure to NE (3223.8 ± 631.55 RFU in the NE group vs. 1072.9 ± 520.29 RFU in the control group); steady ROS production lasted for 2 hours (Figure 1(a)). ROS production was partly inhibited by PEG-SOD (NE + PEG-SOD = 4257 ± 800.0 RFU vs. NE = 6149 ± 626.2 RFU) (Figure 1(a) and PEG-catalase (NE + PEG-CAT = 2330 ± 473.4 RFU vs. NE = 6149 ± 626.2 RFU) (Figure 1(b)) indicating that NE leads to the generation of both superoxide anion and hydrogen peroxide. Incubation of RLMEC with PEG-SOD or PEG-CAT only did not alter ROS production (PEG-SOD = 1204 ± 756.4 RFU and PEG-CAT = 988.7 ± 208.7 RFU) (Figures 1(a)–1(c)). To confirm the effects of NE on ROS production, we assessed ROS generation via a second methodology, oxidation of DCFDA by epifluorescence microscopy. NE increased ROS production (NE = 86350 ± 9380 RFU vs. vehicle = 24677 ± 4712 RFU) in RLMEC, an effect inhibited by both PEG-SOD and PEG-CAT (19138 ± 2531 and 25710 ± 9278, respectively) (Figures 1(d) and 1(e)). Next, to determine the adrenoceptor involved, cells were incubated with phenolamine (10⁻⁸ mol/L) or propranolol (10⁻⁸ mol/L) for 30 minutes before stimulation with NE for 5 minutes. Incubation of RLMEC with only phenolamine (Phen = 1814 ± 285.4) or propranolol (Prop = 1332 ± 94.8) did not alter ROS levels in RLMEC. Cells were then stimulated with NE+phenolamine or NE+propranolol. Whereas phenolamine fully blocked the effects of NE on ROS production (NE + Phen = 2003 ± 290.5 vs. NE = 5832 ± 215.0), propranolol partly inhibited ROS production by NE (NE + Prop = 4815 ± 324.3 vs. NE = 5832 ± 215.0) (Figure 1(f)).

3.2. Nox Activity. NE increased Nox activity in isolated membrane fractions after 5 minutes (in % of control: NE = 140.6 ± 19.12); activity peaked at 15 minutes (NE = 195.4 ± 54.62%) and decreased after 30 minutes (NE = 126.6 ± 25.26%) (Figure 2(a)). Additionally, exposure of RLMEC to NE for 15 minutes increased phosphorylation of p47phox at Ser370 (Figures 2(b) and 2(c)). To assess the contribution of alpha-adrenergic receptor, Nox activity was measured in the presence of phenolamine. Phenolamine completely blocked the increase in Nox activity after exposure to NE (NE + Phen = 83.2 ± 16.01% vs. NE = 146.3 ± 40.13%) (Figure 2(d)). To evaluate the role of β-adrenoceptors in NE-induced Nox activation, cells were treated with propranolol, a nonselective β-adrenoceptor antagonist. Propranolol did not inhibit the effects of NE on Nox activity (in %: NE + Prop = 127.3 ± 13.03 vs. NE = 136.3 ± 36.96) (Figure 2(e)). Incubation of RLMEC with phenolamine or propranolol only did not alter Nox activity (Phen = 100.8 ± 4.28% and Prop = 93.84 ± 7.922%) (Figures 2(d) and 2(e), respectively).

3.3. Nox Expression. Incubation of RLMEC with NE increased Nox2 and Nox4 mRNA expression in RLMEC in a time-dependent manner. Nox2 was the first isoform to
Norepinephrine induces ROS production in rat lung microvascular endothelial cells. Rat lung microvascular endothelial cells (RLMEC) were stimulated with norepinephrine (NE) 5 ng/mL for 120 minutes. (a) NE increases ROS production in RLMEC, an effect inhibited in the presence of PEG-SOD. (b) ROS levels are decreased in the presence of PEG-CAT. (c) Comparative graph illustrating the effects of PEG-SOD and PEG-CAT on ROS production stimulated by the exposure of RLMEC to NE for 5 minutes. (d) Representative images of ROS production by NE in RLMEC assessed by DCF fluorescence; effects of PEG-SOD and PEG-catalase are also shown. (e) Quantification of ROS production assessed by DCF fluorescence: RLMEC were stimulated with NE 5 ng/mL for 15 min in the presence and absence of PEG-SOD and PEG-CAT. (f) Phentolamine (Phen) and propranolol (Prop) had no effects on basal ROS production; Phen inhibited NE-induced ROS production in RLMEC and Prop partly inhibited NE-induced ROS production on RLMEC. *p < 0.05 vs. control, **p < 0.05 vs. NE, ***p < 0.05 vs. NE+PEG-SOD, &p < 0.05 vs. propranolol. N ≥ 5/group.
show increased content after 4 hours (2.5 delta increase relative to control) of RLMEC incubation with NE. Importantly, a gradual increase pattern in Nox2 mRNA was observed (3.29-fold at 8 h and 3.5-fold at 24 h). Nox4 was augmented only 24 hours after cells exposure to NE (2.0-fold). Nox1 mRNA expression was not altered by NE (Figures 3(a)–3(c)).

3.4. NE Induces RLMEC Death. NE decreased the number of viable cells by 10% when compared to control (NE = 86.4 ± 5.41% vs. control = 96.5 ± 2.13%) as assessed by trypan blue. In the presence of apocynin (30 μmol/L), a ROS scavenger in vascular cells, the deleterious effects of NE on cell viability were abolished (NE + APO = 93.3 ± 1.6% vs. NE = 86.4 ± 5.41%). Phentolamine inhibited the deleterious effects of NE on RLMEC viability (Phen + NE = 92.7 ± 1.26% vs. NE = 86.4 ± 5.41%). Apocynin (Apo = 94.2 ± 0.84% vs. control = 96.5 ± 2.13%) or phentolamine (Phen = 93.2 ± 1.5% vs. control = 96.5 ± 2.13%) alone had no effects on cell viability (Figure 4(a)).

To further investigate the effects of NE on cell death, we assessed staining of RLMEC with propidium iodide and annexin V by flow cytometry. NE increased the number of annexin+/PI+ cells by 70% when compared to control (NE = 1.8 ± 0.05% vs. control = 1.1 ± 0.14). In the presence of apocynin, NE-induced cell death, as measured by the number of annexin+/PI+ cells, was inhibited by 50%
To confirm that NE-induced cell death was mediated by alpha-adrenergic receptor activation, we measured caspase-3 inhibitor had no effect on RLMCE death (Phen = 1.21 ± 0.07) (Figures 4(c) and 4(e)).

NE also increased the number of annexin+/PI- cells by 40% compared to control cells (NE = 1.4 ± 0.16 vs. control = 1.0 ± 0.18). This effect was not inhibited by either apocynin (NE + Apo = 1.3 ± 0.1) or phenolamine (NE + Phen = 1.7 ± 0.2) (Figure 4(f)). NE did not alter the number of annexin-/PI+ cells (NE = 0.8 ± 0.08 vs. control = 0.9 ± 0.10) (Figure 4(g)).

In order to pinpoint which Nox-derived reactive oxygen species mediate NE deleterious effects on RLMCE, we assessed RLMCE death in the presence of PEG-SOD and PEG-CAT by two different methodologies: the detection of apoptotic cells by the FargEL DNA fragmentation commercial kit and assessment of DNA fragmentation via electrophoresis. NE induced both DNA fragmentation and appearance of cells in the late apoptotic stage. Those effects were inhibited by PEG-SOD and PEG-CAT (Figures 5(a) and 5(b)).

3.5. Norepinephrine Regulates Caspase-3 by ROS and Alpha-Adrenoceptor-Dependent Mechanisms. To assess the role of reactive oxygen species and \( \alpha_1 \)-adrenoceptors in norepinephrine (NE)-induced caspase-3 activation, RLMCE were treated with apocynin (Apo), phenolamine (Phen), PEG-SOD, or PEG-CAT for 30 minutes before stimulation with NE (5 ng/mL) for 24 h. NE induced the translocation of caspase-3 to the nucleus, an index of caspase-3 activity (Figure 6). Incubation with either apocynin or phenolamine (Figure 6(a)) inhibited nuclear staining of caspase-3. In the same manner, incubation of RLMCE with PEG-SOD inhibited NE-induced caspase-3 activation. Incubation of RLMCE with PEG-CAT had no effect on caspase-3 activation by NE (Figure 6(b)).

3.6. Norepinephrine Induces Rat Lung Microvascular Endothelial Cell Death by Caspase-3-Dependent Mechanisms. NE increased the number of annexin+/PI+ cells identified via flow cytometry when compared to untreated cells (NE = 1.48 ± 0.19 vs. control = 0.99 ± 0.01). In the presence of caspase-3 inhibitor, NE-induced cell death returned to control levels (NE + Casp 3 Inhibitor = 0.92 ± 0.04). Caspase-3 inhibitor had no effects per se on the number of annexin+/PI+ cells (Casp 3 inhibitor = 0.98 ± 0.21 vs. control = 0.99 ± 0.01). No changes were detected in the number of annexin-/PI- or annexin+/PI+ cells (Figures 7(a) and 7(b)).

4. Discussion

The major finding of this study was that NE, at a concentration in the order of magnitude found in plasma of critically ill patients, has deleterious effects on lung microvascular endothelial cells. NE is routinely used in the clinical settings to treat hypotension, at significant higher concentrations, and the immediate effects of NE appear beneficial insofar as NE improves blood pressure and, possibly, short-term patient survival. For example, studies in rats indicate that typical pressor doses of NE can alter pulmonary capillary integrity leading to accumulation of lung water and ultimately pulmonary edema [1, 2]. We therefore investigated the deleterious effects of a clinically relevant concentration of NE on lung endothelial cells. Our findings demonstrate that NE triggers Nox activation and ROS production via \( \alpha_1 \)-adrenoceptors and that the onset of oxidative stress leads to caspase-3 activation, mainly by superoxide anion, which ultimately causes RLMCE death. Collectively, these data suggest that concentrations of NE typically found in critically ill patients may be deleterious to lung endothelial cells.

NE is known to produce ROS in a broad range of cell types via the activation of different adrenoceptors. Deo and
collaborators showed that NE increases ROS production in human peripheral blood mononuclear cells (PBMCs) via \( \alpha_2 \)-adrenoceptors [3]. NE also induces ROS generation in U937 macrophages via beta-adrenergic signaling as evidenced by the reversal of ROS production to basal levels when U937 cells were pretreated with propranolol [5]. Here,
we show that, in RLMEC, NE induces Nox-dependent ROS production by activation of α₁-adrenoceptors since phentolamine, a specific α₁-adrenoceptor antagonist, abolishes NE-induced ROS production. Furthermore, incubation of RLMEC with propranolol, a nonspecific antagonist of β-adrenoceptors, did not inhibit NE-induced Nox activation. In addition, we found that incubation of RLMEC with either PEG-SOD or PEG-catalase partly inhibits NE-induced ROS production indicating NE can promote generation of both superoxide anion and hydrogen peroxide. Propranolol, a nonselective β-adrenoceptor antagonist, partly inhibited ROS production by NE but did not alter the increase in Nox activity induced by NE, suggesting that exposure to NE may result in increased ROS production by different pathways in RLMEC. Herein, we focused on investigating how Nox-driven ROS may contribute to cell death in RLMEC exposed to NE.

Nox is the main source of ROS in the vasculature. Interestingly, different Nox isoforms preferentially generate hydrogen peroxide over superoxide anion. Nox2 is the main isoform present in endothelial cells and it is known to constitutively generate superoxide anion in basal conditions. The fact that we detected increased production of both superoxide anion and hydrogen peroxide in cells treated with NE suggests that a different source of ROS, such as mitochondrial, may also participate in the deleterious effects of NE. Our findings show that apocynin, a ROS scavenger/antioxidant in vascular cells, decreases the number of annexin+/PI+ cells but does not change the number of annexin+/PI- cells. Moreover, incubation of RLMEC with either PEG-SOD or PEG-CAT inhibit the effects of NE on DNA fragmentation. These findings support the idea that NE may act via additional pathways that contribute to its toxic effects on endothelial cells. It is important to mention that the effects of apocynin in vascular cells is not directly related to Nox activity as vascular cells lack myeloperoxidase and are not able to dimerize apocynin [12]. Further studies are required to identify additional mechanisms of NE actions on endothelial cells. NE has been shown to increase ROS generation in cardiac endothelial cells, albeit at concentrations over 1000-fold higher than we used in this study [13]. Xiong and collaborators showed that NE augments ROS production in embryonic ventricular myocyte H9c2 cells via selective increase in Nox1 expression [4], but others found that NE-induced ROS production occurs by Nox2-dependent pathways in adult cardiac myocytes [14, 15]. In PBMCs, ROS production
was associated with increased gp91phox, p22phox, and p67phox mRNA expressions. Collectively, these reports corroborate our findings that NE induces ROS production via Nox-dependent mechanisms. Notably, ours is the first report to highlight the effects of physiological concentrations of NE on ROS production and Nox activity.

The effects of ROS on the vasculature vary according to source and cell type. Herein, we show that NE-induced ROS results in caspase-3 activation and RLMEC death. Our data corroborate studies in the literature that report ROS activators of caspase-3-mediated apoptosis is triggered by different stimuli. Particularly in EC, ROS have been shown to mediate TNF-induced Nox4 caspase-3 activity and Bcl1 expression in HUVEC [16]. Tian and collaborators also reported a role for Nox4 in caspase-mediated endothelial cell death in inflammatory conditions [17]. Park and collaborators reported the specific role of superoxide anion in lysophosphatidylcholine-induced caspase-3 activation and apoptosis in HUVEC [18]. Likewise, Tawfik and colleagues reported that exogenous addition of hydrogen peroxide or hyperglycemia-stimulated ROS activates caspase3-induced cell death via JAK2-dependent pathways in aortic endothelial cells [19]. Our data indicate that NE induces production of both superoxide anion and hydrogen peroxide via Nox2- and Nox4-dependent mechanisms.

Fu and collaborators reported that micromolar concentrations of NE induce neonatal rat endothelial cell death by ROS-dependent activation of c-jun N-terminal kinase (JNK) [13]. The same group also showed that this effect is mediated by caspases 2 and 3 via beta-adrenergic signaling, with no contribution of α1-adrenoceptors [20, 21]. Taken together, these data support our findings of NE increasing ROS production by α1- and β-adrenoceptor signaling and corroborate our finding that in NE-induced caspase-3 activation. They have also reported that production of ROS by NE is a NADPH-independent mechanism. The fact that they have not found a role for α-adrenoceptor signaling in NE-induced apoptosis and described a different pathway for ROS formation can be potentially related to the adrenoceptor subtype in the studied cell type and or be a tissue-dependent phenomenon.

Herein, we showed that NE can result in RLMEC death by two different assessments, cell viability via trypan blue staining and cell death by annexin V and PI double positive staining. Annexin V is an early marker for apoptosis and may occur in late stages of different forms of cell death such as necrosis. In the same way, PI positive staining is usually a marker for necrosis but it may occur in the later stages of apoptosis. Further studies are necessary to clarify what type of cell death is predominant when endothelial cells are exposed to clinically found concentrations of NE.

5. Conclusion and Clinical Significance

The results presented here demonstrate a potential adverse effect of NE at concentrations expected in a clinical setting.
These findings suggest that exposure of lung endothelial cells to supraphysiological doses of NE could be harmful to patients as it triggers lung endothelial cells death. Further studies are necessary to address the potential deleterious effects of NE in clinical settings.

Abbreviations

PEG-catalase: Catalase-polyethylene glycol
DHE: Dihydroethidium
NADPH: Dihydronicotinamide-adenine dinucleotide phosphate
RLMEC: Rat lung microvascular endothelial cells
Nox: NADPH oxidase
NE: Norepinephrine
PI: Propidium iodide
ROS: Reactive oxygen species
RIPA buffer: Radioimmunoprecipitation assay buffer
PEG-SOD: Superoxide dismutase-polyethylene glycol
TBS-T: Tris-buffered saline-Tween 20.

Figure 7: Norepinephrine induces cell death via caspase-3-dependent pathways. Rat lung microvascular endothelial cell (RLMEC) death was assessed by measurement of annexin and propidium iodide staining by flow cytometry after stimulation with norepinephrine (5 ng/mL). To assess the role of caspase-3 in NE-induced cell death, RLMEC were treated with caspase-3 inhibitor. (a) NE increases the number of annexin+/PI+ cells as indicated by arrows. (b) Bar graph corresponding to the quantification of annexin+/PI+ cells in cells treated and nontreated with NE, in the presence or absence of caspase-3 inhibitor. * p < 0.05 vs. control and ** p < 0.05 vs. NE; N ≥ 3/group.
Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors have no conflicts of interest to declare.

Authors’ Contributions
AZC contributed to the study conception and design, performed experiments, collected and interpreted data, and wrote the manuscript. RD contributed to the data interpretation and wrote the manuscript. GW contributed to the data interpretation and wrote the manuscript.

Acknowledgments
We thank the support of David E. Schwartz MD, Chairman of the Department of Anesthesiology at University of Illinois at Chicago and the support of Jerry McCoy MD, Chairman of the Department of Anesthesiology at University of Arizona for providing funds for the presented work.

References
[1] V. Krishnamoorthy, D. B. Hiller, R. Ripper et al., “Epinephrine induces rapid deterioration in pulmonary oxygen exchange in intact, anesthetized rats: a flow and pulmonary capillary pressure-dependent phenomenon,” Anesthesiology, vol. 117, no. 4, pp. 745–754, 2012.
[2] A. Z. Chignalia, A. Isbatan, M. Patel et al., “Pressure-dependent NOS activation contributes to endothelial hyperpermeability in a model of acute heart failure,” Bioscience Reports, vol. 38, no. 6, 2018.
[3] S. H. Deo, N. T. Jenkins, J. Padilla, A. R. Parrish, and P. J. Fadel, “Norepinephrine increases NADPH oxidase-derived superoxide in human peripheral blood mononuclear cells via α-adrenergic receptors,” American Journal of Physiology Regulatory, Integrative and Comparative Physiology, vol. 305, no. 10, pp. Ri1124–Ri1132, 2013.
[4] F. Xiong, D. Xiao, and L. Zhang, “Norepinephrine causes epigenetic repression of PKCε gene in rodent hearts by activating Nox1-dependent reactive oxygen species production,” The FASEB Journal, vol. 26, no. 7, pp. 2753–2763, 2012.
[5] M. Li, W. Yao, S. Li, and J. Xi, “Norepinephrine induces the expression of interleukin-6 via β-adrenoreceptor- NAD(P)H oxidase system -NF-κB dependent signal pathway in U937 macrophages,” Biochemical and Biophysical Research Communications, vol. 460, no. 4, pp. 1029–1034, 2015.
[6] S. Naganathar, H. D. de’Ath, J. Wall, and K. Brohi, “Admission biomarkers of trauma-induced secondary cardiac injury predict adverse cardiac events and are associated with plasma catecholamine levels,” Journal of Trauma and Acute Care Surgery, vol. 79, no. 1, pp. 71–77, 2015.
[7] P. Moliner, C. Enjuanes, M. Tajes et al., “Association between norepinephrine levels and abnormal iron status in patients with chronic heart failure: is iron deficiency more than a comorbidity?,” Journal of the American Heart Association, vol. 8, no. 4, article e010887, 2019.
[8] S. R. Ostrowski, A. Sørensen, C. F. Larsen, and P. I. Johansson, “Thrombelastography and biomarker profiles in acute coagulopathy of trauma: a prospective study,” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, vol. 19, no. 1, p. 64, 2011.
[9] D. C. Fernandes, J. Wosniak Jr., L. A. Pescatore et al., “Analysis of DHE-derived oxidation products by HPLC in the assessment of superoxide production and NADPH oxidase activity in vascular systems,” American Journal of Physiology-Cell Physiology, vol. 292, no. 1, pp. C413–C422, 2007.
[10] A. Z. Chignalia, M. A. Oliveira, V. Debbas et al., “Testosterone induces leucocyte migration by NADPH oxidase- driven ROS- and COX2-dependent mechanisms,” Clinical Science, vol. 129, no. 1, pp. 39–48, 2015.
[11] D. C. Fernandes, R. C. Goncalves, and F. R. Laurindo, “Measurement of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation,” Methods in Molecular Biology, vol. 1527, pp. 233–249, 2017.
[12] S. Heumüller, S. Wind, E. Barbosa-Sicard et al., “Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant,” Hypertension, vol. 51, no. 2, pp. 211–217, 2008.
[13] Y. C. Fu, S. C. Yin, C. S. Chi, B. Hwang, and S. L. Hsu, “Norepinephrine induces apoptosis in neonatal rat endothelial cells via a ROS-dependent JNK activation pathway,” Apoptosis, vol. 11, no. 10, pp. 2053–2063, 2006.
[14] Y. Li, J. M. Arnold, M. Pampillo, A. V. Babwah, and T. Peng, “Taurine prevents cardiomyocyte death by inhibiting NADPH oxidase- mediated calpain activation,” Free Radical Biology and Medicine, vol. 46, no. 1, pp. 51–61, 2009.
[15] N. Saleem, A. Prasad, and S. K. Goswami, “Apocynin prevents isoproterenol-induced cardiac hypertrophy in rat,” Molecular and Cellular Biochemistry, vol. 445, no. 1-2, pp. 79–88, 2018.
[16] F. Xia, C. Wang, Y. Jin et al., “Luteolin protects HUVECs from TNF-α-induced oxidative stress and inflammation via its effects on the Nox4/ROS-NF-κB and MAPK pathways,” Journal of Atherosclerosis and Thrombosis, vol. 21, no. 8, pp. 768–783, 2014.
[17] X. Y. Tian, L. H. Yung, W. T. Wong et al., “Bone morphogenic protein-4 induces endothelial cell apoptosis through oxidative stress-dependent p38MAPK and JNK pathway,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 1, pp. 237–244, 2012.
[18] S. Park, J. A. Kim, S. Choi, and S. H. Suh, “Superoxide is a potential culprit of caspase-3 dependent endothelial cell death induced by lysophosphatidylcholine,” Journal of Physiology and Pharmacology, vol. 61, no. 4, pp. 375–381, 2010.
[19] A. Tawfiq, L. Jin, A. K. L. Banes-Berceli et al., “Hyperglycemia and reactive oxygen species mediate apoptosis in aortic endothelial cells through Janus kinase 2,” Vascular Pharmacology, vol. 43, no. 5, pp. 320–326, 2005.
[20] Y. C. Fu, C. S. Chi, S. C. Yin, B. Hwang, Y. T. Chiu, and S. L. Hsu, “Norepinephrine induces apoptosis in neonatal rat endothelial cells via down-regulation of Bcl-2 and activation of β-adrenergic and caspase-2 pathways,” Cardiovascular Research, vol. 61, no. 1, pp. 143–151, 2004.
[21] Y. C. Fu, C. S. Chi, S. C. Yin, B. Hwang, Y. T. Chiu, and S. L. Hsu, “Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF-α-caspase signaling pathway,” Cardiovascular Research, vol. 62, no. 3, pp. 558–567, 2004.